Please login to the form below
ViiV
This page shows the latest ViiV news and features for those working in and with pharma, biotech and healthcare.
GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention
ViiV Healthcare, which is majority-owned by GSK, has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of cabotegravir long-acting injectable for pre-exposure ... Kimberly Smith, head of
Latest news
-
GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention
ViiV Healthcare, which is majority-owned by GSK, and the Medicines Patent Pool (MPP) have signed a new voluntary licensing agreement to expand access to HIV prevention in the developing world, ... Deborah Waterhouse, chief executive officer at ViiV
-
2022 PM Society Awards
Other client Gold winners were Allergan Aesthetics, an AbbVie Company, Campaign Against Living Miserably (CALM), Fresenius Kabi, Greenwich BioSciences, Mölnlycke, Novo Nordisk, Roche/Chugai, Sanofi Genzyme and ViiV Healthcare.
-
FDA issues approval for Janssen’s HIV drug Cabenuva
The long-acting HIV treatment is part of a collaborative development between Janssen and Viiv Healthcare. ... Cabenuva is made up of two separate injectable medicines – rilpivirine, Janssen’s single-dose vial injectable and Viiv Healthcare’s
-
NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen
The regimen combines Vocabria, a long-acting form of cabotegravir developed by ViiV Healthcare (global specialist HIV company majority owned by GSK), and Rekambys, a long-acting form of rilpivirine developed
-
GSK considers more divestments to help R&D push
HIV sales through the ViiV Healthcare joint venture showed signs of weakness, as Tivicay (dolutegravir) continued to decline in the face of strong competition from Gilead Sciences, particularly its fast-growing ... There was an acceleration in sales of
More from news
Approximately 40 fully matching, plus 69 partially matching documents found.
Latest Intelligence
-
Maintaining continuity of care in Ukraine as conflict continues
To meet the needs of this population, through ViiV Healthcare, GSK has been making significant donations of antiretroviral medicines available to WHO, national AIDS programmes and NGO partners to support children
-
The human connection: how to achieve emotive creativity in pharma
This is Living with Cancer or ViiV Healthcare’s U=U.
-
Awards or not, what really matters is... can you make it mean something?
The U=U campaign. This was the case with our U=U campaign we developed with ViiV in 2019.
-
Pharma industry consensus: fix data strategy before pushing artificial intelligence and machine learning applications
and their application to commercial actions,” said Raakhi. Jeff French, Vice President and Chief Digital Officer, ViiV Healthcare, puts forth compliance and understanding as more fundamental issues for AI and ML
-
Re-imagining content supply chains for a next-gen customer experience in pharma
According to Jeff French, Vice President and Chief Digital Officer at ViiV Healthcare: “From a content supply chain perspective, I think the key point is getting the planning right in terms
More from intelligence
Approximately 2 fully matching, plus 12 partially matching documents found.
Latest appointments
-
New starters join Four Communications, Emotive and McCann Health
Mitchell, who spent a placement year working at ViiV Healthcare, has a degree in Biology.
-
Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
the former director of government affairs and policy at Gilead, ViiV Healthcare and GSK.
-
GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet
Limet has served as ViiV's CEO since its 2009 formation as a partnership between GSK and Pfizer, with Shionogi subsequently joining the venture in 2012. ... He said: “Establishing and then leading ViiV Healthcare for the past seven years has been an
-
Phil Golz appointed commercial director at HealthUnlocked
Moves from ViiV Healthcare to join the socialnetwork for health. Health social network HealthUnlocked has appointed Phil Golz to the newly-created role of commercial director. ... He joins the company from ViiV Healthcare, where he was executive director,
More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
“My first six months in medical communications” – views from an emotive graduate recruit, Claire
She has a BSc in Biology and a year’s experience working at ViiV Healthcare.
-
Havas Lynx Group
Sanofi. Siemens. Teva. UCB. ViiV.
-
EPG Health
Pierre Fabre, Roche, Sandoz, Sanofi, Seagen, Takeda, Teva, ViiV Healthcare.
-
Havas Lynx Group lifts a silver Cannes Lion with landmark HIV campaign
Developed for ViiV Healthcare and in partnership with 13 different UK HIV charities, the company’s team of creatives and digital specialists gained a true understanding of the impact of what
-
emotive takes Gold and Silver at PM Society Digital Awards 2018!
emotive took Gold and Silver last night at the PM Society Digital Awards for their interactive medical education case study programme for ViiV Healthcare. ... The success of the project has led to the ART Perspectives programme being implemented all over
More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
Evoke Mind+Matter
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
